Try our Advanced Search for more refined results

FEDERAL TRADE COMMISSION v. SURESCRIPTS, LLC

  1. July 27, 2023

    FTC Cuts Deal Ending Surescripts Monopoly Case

    The Federal Trade Commission reached a settlement Thursday with Surescripts to end a case alleging the electronic prescription service provider used contract terms and other tactics to illegally maintain its monopoly over two related markets.

  2. July 13, 2023

    FTC Nears Deal To End Surescripts Monopoly Case

    Federal Trade Commission staffers reached an agreement Thursday with Surescripts to end an enforcement action alleging the company used contract terms and other tactics to illegally maintain its monopoly over electronic prescription services.

  3. March 31, 2023

    Surescripts Holds Monopoly In E-Prescriptions, Judge Says

    A D.C. federal judge on Thursday granted the Federal Trade Commission a partial win in its antitrust case against Surescripts, ruling the company holds monopoly power in the e-prescriptions market, and its 95% share since 2010 is "surely dominance by any definition or metric."

  4. March 16, 2023

    Surescripts, FTC 'Ought To Be Talking Again,' Judge Says

    A D.C. federal judge suggested Thursday that the Federal Trade Commission go back to the negotiating table in a case alleging Surescripts uses exclusive contract terms to maintain a monopoly in e-prescriptions, because the company is phasing out the loyalty programs at the heart of those allegations.

  5. March 13, 2023

    Surescripts Says Loyalty Programs' End Moots FTC Case

    A D.C. federal judge teed up a new fight Sunday in the Federal Trade Commission case alleging Surescripts uses exclusive contract terms to maintain a monopoly in e-prescriptions, after Surescripts said that it was phasing out its loyalty programs and thus rendering the FTC suit moot.

  6. August 17, 2022

    Surescript's EpiPen Citation 'Nothing New,' FTC Says

    The Federal Trade Commission assailed Surescripts for telling a D.C. federal judge that a Tenth Circuit decision sparing Mylan from antitrust allegations over the EpiPen bolsters Surescripts' bid to escape claims it uses exclusive contract terms to maintain a monopoly in e-prescriptions.

  7. May 17, 2021

    FTC Takes Disgorgement Off Table In Surescripts Case

    The Federal Trade Commission won't be seeking disgorgement in its monopoly case against electronic prescription service Surescripts after the U.S. Supreme Court ruled that the agency doesn't have the power to seek the return of ill-gotten gains when launching antitrust actions.

  8. April 28, 2021

    Rollback Of Restitution Power Leaves FTC Cases In Limbo

    The U.S. Supreme Court's ruling last week in AMG Capital v. FTC all but stripped the Federal Trade Commission of its ability to recoup money from lawbreakers in federal court and the agency's pending cases are sure to feel the impact.

  9. April 28, 2021

    Justices' Restitution Order May Allow FTC-Surescripts Deal

    The Federal Trade Commission's high court drubbing over its claimed authority to recover ill-gotten gains in federal court may have created a pathway to settlement in the FTC's monopolization case against Surescripts, the e-prescription service said during a status conference Wednesday.

  10. July 14, 2020

    FTC, Surescripts Debate Liu's Impact On Monopolization Case

    The Federal Trade Commission and Surescripts offered dueling interpretations of how the antitrust watchdog's monopolization case against the e-prescription service is potentially impacted by the U.S. Supreme Court's recent holding that the U.S. Securities and Exchange Commission has the ability to collect disgorgement — with some new parameters.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!